Dossier assessment

Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A19-98
Last updated

Report documents

  1. Extract of dossier assessment

    Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 446 kB, EN, not accessible
  2. Dossier assessment

    Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 836 kB, DE, not accessible

Dossier assessment

Indication:

Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer if prior adjuvant trastuzumab-based therapy was completed less than one year ago

Result of dossier assessment:

An advantage in the outcome "recurrence" is accompanied by major disadvantages in side effects during the treatment phase; added benefit not proven

Project details

Project no.
A19-98
Commission
Commission awarded on 29.11.2019 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Neratinib (breast cancer) - Addendum to Commission A19-98

    Project no.
    A20-40
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form